PER 1.35% 7.5¢ percheron therapeutics limited

Sarepta has far too much Debt !Anp will not follow in their...

  1. 13,139 Posts.
    lightbulb Created with Sketch. 1376
    Sarepta has far too much Debt !
    Anp will not follow in their footsteps
    Also Sarepta has only 17% of DMD ambulant boys ( yet to provide FDA with efficacy data )
    The point being Boomy
    Anti inflammation drug in combination with a multitude of diseases is a much bigger market .
    Just in the US by 2030 $10 billion for DMD
    Limb Girdle $2 billion
    Asthma $21 billion
    MS $$$?
    whether you like it or not Sarepta is a pathetic comparison:
    Sorry dude






 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.5¢
Change
0.001(1.35%)
Mkt cap ! $67.61M
Open High Low Value Volume
7.7¢ 7.8¢ 7.4¢ $24.63K 325.4K

Buyers (Bids)

No. Vol. Price($)
2 142779 7.3¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 8181 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.